Sihuan Projects 217% Profit Growth, but 39x Earnings Still Look Expensive

Sihuan's profit guide is strong, but the multiple still looks rich

Sihuan is guiding to very strong profit growth, yet at 39.1x P/E the stock still looks expensive. The key question is not whether results are improving, but how much of that improvement depends on items the market may not fully trust.

Management is offering more than vague optimism. Sihuan has guided to at least RMB1,140 million revenue and at least RMB210 million net profit, implying at least 217.2% net-profit growth. That is a meaningful rebound. But strong headline growth can also distract from a harder question: is this the start of a more durable earnings base, or a temporary mix of better operations and less recurring income items?

Why valuation matters more than the headline

Sentiment has already reset. Sihuan shares declined 25.82% over the past 90 days, trade below the average analyst price target, and still sit above some intrinsic value estimates. That leaves the stock in a delicate spot: expectations have fallen, but not clearly enough to make the current multiple look conservative.

If new earnings prove durable, the multiple can look reasonable in time. If the profit mix is less persistent than the headline suggests, valuation compression can arrive before the business does.

Medical aesthetics looks like the sturdiest part of the turnaround

The more durable part of Sihuan's story is its medical aesthetics franchise. The company expects that segment to deliver revenue of no less than RMB680 million and segment profit of not less than RMB320 million. Management also says the business maintained steady development, helped by Letybo, regenerative products such as PLLA and PCL, and functional aesthetics products. That is the clearest sign of a recurring operating engine.

The rest of the profit guide looks less clean. Sihuan also expects share of profits of not less than RMB 110 million for the Period mainly due to a successful IPO of an associate. The source text also refers to asset divestments as a factor in the guidance, reinforcing the point that some of the profit increase may come from items that do not repeat in the same form.

That distinction matters. A strong profit-growth headline can improve sentiment quickly, but it does not automatically mean the quality of earnings has improved in a lasting way.

What would make the valuation work, and what could break it

A stronger half-year guide is necessary, but it is no longer sufficient on its own. After a recent swing in sentiment, the next repricing will depend less on another optimistic headline and more on whether management can turn the guide into repeatable operating performance.

Signals that could support the multiple

• Medical aesthetics remains the stable profit core, with demand for Letybo and adjacent products staying firm.
• The innovative drug business keeps advancing commercially, with consolidated revenue achieving significant growth and net loss being substantially reduced.
• Associate and divestment-related gains do not make up such a large share of total profit that the recurring earnings base becomes unclear.

Signals that could pressure the multiple

• Demand weakens in the medical aesthetics franchise.
• Associate profits or divestment benefits fall short, reducing the durability of the profit rebound.
• Commercialization progress does not translate into clearer, more recurring profitability.

If the durable parts of the business improve as expected, the market may be willing to look past today's skepticism. If not, the multiple is likely to prove more fragile than the headline growth rate suggests.